Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group

Lansoprazole is a H+.K(+)-ATPase (proton pump) inhibitor with an anti-secretory action and is therefore potentially useful in the treatment of gastro-oesophageal reflux. This study was conducted to determine the efficacy and short-term safety of lansoprazole at doses of 30 mg or 60 mg once daily, co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 1995-04, Vol.9 (2), p.145
Hauptverfasser: Bardhan, K D, Hawkey, C J, Long, R G, Morgan, A G, Wormsley, K G, Moules, I K, Brocklebank, D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 145
container_title Alimentary pharmacology & therapeutics
container_volume 9
creator Bardhan, K D
Hawkey, C J
Long, R G
Morgan, A G
Wormsley, K G
Moules, I K
Brocklebank, D
description Lansoprazole is a H+.K(+)-ATPase (proton pump) inhibitor with an anti-secretory action and is therefore potentially useful in the treatment of gastro-oesophageal reflux. This study was conducted to determine the efficacy and short-term safety of lansoprazole at doses of 30 mg or 60 mg once daily, compared with ranitidine 150 mg twice daily, in the treatment of patients with reflux oesophagitis. This was a double-blind, stratified, randomized, comparative, parallel group study conducted in five centres in the UK. A total of 229 patients (155 men) aged 18-79 years with endoscopically-confirmed oesophagitis were randomized to receive lansoprazole 30 mg p.o. daily, lansoprazole 60 mg p.o. daily, or ranitidine 150 mg p.o. b.d. Efficacy was assessed by endoscopic examination at 4 weeks and 8 weeks, together with symptom relief and antacid usage. Lansoprazole 30 mg and 60 mg were superior at 4 and 8 weeks (P < 0.01) to ranitidine in healing reflux oesophagitis: respective healing rates being 84%, 72% and 39% after 4 weeks and 92%, 91% and 53% after 8 weeks. Relief of heartburn with lansoprazole 30 mg and 60 mg was superior to that achieved with ranitidine at both week 4 (P < 0.01) and week 8 (P < 0.02). Sixty-four patients experienced a total of 85 adverse events, one-third of which were considered drug-related. The incidence and severity were similar in the three groups. Lansoprazole 30 mg and 60 mg once daily are more effective than ranitidine 150 mg twice daily in the short-term treatment of reflux oesophagitis.
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_7605854</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>7605854</sourcerecordid><originalsourceid>FETCH-LOGICAL-p534-a57e3898a0fe96c60ec39a3e9b29216582343ed274e0e6ec77298fb84835f0623</originalsourceid><addsrcrecordid>eNpVj81KxDAURrNQxnH0EYS8QCWTNH9LKTqKBUHG9XDb3thI24SkFfXpHXA2rr7NOQe-M7JmXNmCm624IJc5fzDGlGZ8RVZaMWlkuSaxhimHmOAnDEg_MeUl0wSTn33nJ6QuJDr3SOeEMI84zTQ4mtANyxcNeDR7eD-y-Za-PdN_rWrwk29hoK-YEVLb010KS7wi5w6GjNen3ZD9w_2-eizql91TdVcXUYqyAKlRGGuAObSqVQxbYUGgbbjlWyUNF6XAjusSGSpstebWuMaURkjHFBcbcvOXjUszYneIyY-Qvg-n4-IX_aRVRA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Bardhan, K D ; Hawkey, C J ; Long, R G ; Morgan, A G ; Wormsley, K G ; Moules, I K ; Brocklebank, D</creator><creatorcontrib>Bardhan, K D ; Hawkey, C J ; Long, R G ; Morgan, A G ; Wormsley, K G ; Moules, I K ; Brocklebank, D</creatorcontrib><description>Lansoprazole is a H+.K(+)-ATPase (proton pump) inhibitor with an anti-secretory action and is therefore potentially useful in the treatment of gastro-oesophageal reflux. This study was conducted to determine the efficacy and short-term safety of lansoprazole at doses of 30 mg or 60 mg once daily, compared with ranitidine 150 mg twice daily, in the treatment of patients with reflux oesophagitis. This was a double-blind, stratified, randomized, comparative, parallel group study conducted in five centres in the UK. A total of 229 patients (155 men) aged 18-79 years with endoscopically-confirmed oesophagitis were randomized to receive lansoprazole 30 mg p.o. daily, lansoprazole 60 mg p.o. daily, or ranitidine 150 mg p.o. b.d. Efficacy was assessed by endoscopic examination at 4 weeks and 8 weeks, together with symptom relief and antacid usage. Lansoprazole 30 mg and 60 mg were superior at 4 and 8 weeks (P &lt; 0.01) to ranitidine in healing reflux oesophagitis: respective healing rates being 84%, 72% and 39% after 4 weeks and 92%, 91% and 53% after 8 weeks. Relief of heartburn with lansoprazole 30 mg and 60 mg was superior to that achieved with ranitidine at both week 4 (P &lt; 0.01) and week 8 (P &lt; 0.02). Sixty-four patients experienced a total of 85 adverse events, one-third of which were considered drug-related. The incidence and severity were similar in the three groups. Lansoprazole 30 mg and 60 mg once daily are more effective than ranitidine 150 mg twice daily in the short-term treatment of reflux oesophagitis.</description><identifier>ISSN: 0269-2813</identifier><identifier>PMID: 7605854</identifier><language>eng</language><publisher>England</publisher><subject>2-Pyridinylmethylsulfinylbenzimidazoles ; Adult ; Aged ; Double-Blind Method ; Esophagitis, Peptic - drug therapy ; Follow-Up Studies ; H(+)-K(+)-Exchanging ATPase - pharmacology ; Headache - chemically induced ; Humans ; Lansoprazole ; Male ; Middle Aged ; Omeprazole - adverse effects ; Omeprazole - analogs &amp; derivatives ; Omeprazole - therapeutic use ; Proton Pump Inhibitors ; Ranitidine - adverse effects ; Ranitidine - therapeutic use ; Treatment Outcome</subject><ispartof>Alimentary pharmacology &amp; therapeutics, 1995-04, Vol.9 (2), p.145</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7605854$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bardhan, K D</creatorcontrib><creatorcontrib>Hawkey, C J</creatorcontrib><creatorcontrib>Long, R G</creatorcontrib><creatorcontrib>Morgan, A G</creatorcontrib><creatorcontrib>Wormsley, K G</creatorcontrib><creatorcontrib>Moules, I K</creatorcontrib><creatorcontrib>Brocklebank, D</creatorcontrib><title>Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group</title><title>Alimentary pharmacology &amp; therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Lansoprazole is a H+.K(+)-ATPase (proton pump) inhibitor with an anti-secretory action and is therefore potentially useful in the treatment of gastro-oesophageal reflux. This study was conducted to determine the efficacy and short-term safety of lansoprazole at doses of 30 mg or 60 mg once daily, compared with ranitidine 150 mg twice daily, in the treatment of patients with reflux oesophagitis. This was a double-blind, stratified, randomized, comparative, parallel group study conducted in five centres in the UK. A total of 229 patients (155 men) aged 18-79 years with endoscopically-confirmed oesophagitis were randomized to receive lansoprazole 30 mg p.o. daily, lansoprazole 60 mg p.o. daily, or ranitidine 150 mg p.o. b.d. Efficacy was assessed by endoscopic examination at 4 weeks and 8 weeks, together with symptom relief and antacid usage. Lansoprazole 30 mg and 60 mg were superior at 4 and 8 weeks (P &lt; 0.01) to ranitidine in healing reflux oesophagitis: respective healing rates being 84%, 72% and 39% after 4 weeks and 92%, 91% and 53% after 8 weeks. Relief of heartburn with lansoprazole 30 mg and 60 mg was superior to that achieved with ranitidine at both week 4 (P &lt; 0.01) and week 8 (P &lt; 0.02). Sixty-four patients experienced a total of 85 adverse events, one-third of which were considered drug-related. The incidence and severity were similar in the three groups. Lansoprazole 30 mg and 60 mg once daily are more effective than ranitidine 150 mg twice daily in the short-term treatment of reflux oesophagitis.</description><subject>2-Pyridinylmethylsulfinylbenzimidazoles</subject><subject>Adult</subject><subject>Aged</subject><subject>Double-Blind Method</subject><subject>Esophagitis, Peptic - drug therapy</subject><subject>Follow-Up Studies</subject><subject>H(+)-K(+)-Exchanging ATPase - pharmacology</subject><subject>Headache - chemically induced</subject><subject>Humans</subject><subject>Lansoprazole</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Omeprazole - adverse effects</subject><subject>Omeprazole - analogs &amp; derivatives</subject><subject>Omeprazole - therapeutic use</subject><subject>Proton Pump Inhibitors</subject><subject>Ranitidine - adverse effects</subject><subject>Ranitidine - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0269-2813</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVj81KxDAURrNQxnH0EYS8QCWTNH9LKTqKBUHG9XDb3thI24SkFfXpHXA2rr7NOQe-M7JmXNmCm624IJc5fzDGlGZ8RVZaMWlkuSaxhimHmOAnDEg_MeUl0wSTn33nJ6QuJDr3SOeEMI84zTQ4mtANyxcNeDR7eD-y-Za-PdN_rWrwk29hoK-YEVLb010KS7wi5w6GjNen3ZD9w_2-eizql91TdVcXUYqyAKlRGGuAObSqVQxbYUGgbbjlWyUNF6XAjusSGSpstebWuMaURkjHFBcbcvOXjUszYneIyY-Qvg-n4-IX_aRVRA</recordid><startdate>199504</startdate><enddate>199504</enddate><creator>Bardhan, K D</creator><creator>Hawkey, C J</creator><creator>Long, R G</creator><creator>Morgan, A G</creator><creator>Wormsley, K G</creator><creator>Moules, I K</creator><creator>Brocklebank, D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>199504</creationdate><title>Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group</title><author>Bardhan, K D ; Hawkey, C J ; Long, R G ; Morgan, A G ; Wormsley, K G ; Moules, I K ; Brocklebank, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p534-a57e3898a0fe96c60ec39a3e9b29216582343ed274e0e6ec77298fb84835f0623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>2-Pyridinylmethylsulfinylbenzimidazoles</topic><topic>Adult</topic><topic>Aged</topic><topic>Double-Blind Method</topic><topic>Esophagitis, Peptic - drug therapy</topic><topic>Follow-Up Studies</topic><topic>H(+)-K(+)-Exchanging ATPase - pharmacology</topic><topic>Headache - chemically induced</topic><topic>Humans</topic><topic>Lansoprazole</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Omeprazole - adverse effects</topic><topic>Omeprazole - analogs &amp; derivatives</topic><topic>Omeprazole - therapeutic use</topic><topic>Proton Pump Inhibitors</topic><topic>Ranitidine - adverse effects</topic><topic>Ranitidine - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bardhan, K D</creatorcontrib><creatorcontrib>Hawkey, C J</creatorcontrib><creatorcontrib>Long, R G</creatorcontrib><creatorcontrib>Morgan, A G</creatorcontrib><creatorcontrib>Wormsley, K G</creatorcontrib><creatorcontrib>Moules, I K</creatorcontrib><creatorcontrib>Brocklebank, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bardhan, K D</au><au>Hawkey, C J</au><au>Long, R G</au><au>Morgan, A G</au><au>Wormsley, K G</au><au>Moules, I K</au><au>Brocklebank, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group</atitle><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>1995-04</date><risdate>1995</risdate><volume>9</volume><issue>2</issue><spage>145</spage><pages>145-</pages><issn>0269-2813</issn><abstract>Lansoprazole is a H+.K(+)-ATPase (proton pump) inhibitor with an anti-secretory action and is therefore potentially useful in the treatment of gastro-oesophageal reflux. This study was conducted to determine the efficacy and short-term safety of lansoprazole at doses of 30 mg or 60 mg once daily, compared with ranitidine 150 mg twice daily, in the treatment of patients with reflux oesophagitis. This was a double-blind, stratified, randomized, comparative, parallel group study conducted in five centres in the UK. A total of 229 patients (155 men) aged 18-79 years with endoscopically-confirmed oesophagitis were randomized to receive lansoprazole 30 mg p.o. daily, lansoprazole 60 mg p.o. daily, or ranitidine 150 mg p.o. b.d. Efficacy was assessed by endoscopic examination at 4 weeks and 8 weeks, together with symptom relief and antacid usage. Lansoprazole 30 mg and 60 mg were superior at 4 and 8 weeks (P &lt; 0.01) to ranitidine in healing reflux oesophagitis: respective healing rates being 84%, 72% and 39% after 4 weeks and 92%, 91% and 53% after 8 weeks. Relief of heartburn with lansoprazole 30 mg and 60 mg was superior to that achieved with ranitidine at both week 4 (P &lt; 0.01) and week 8 (P &lt; 0.02). Sixty-four patients experienced a total of 85 adverse events, one-third of which were considered drug-related. The incidence and severity were similar in the three groups. Lansoprazole 30 mg and 60 mg once daily are more effective than ranitidine 150 mg twice daily in the short-term treatment of reflux oesophagitis.</abstract><cop>England</cop><pmid>7605854</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0269-2813
ispartof Alimentary pharmacology & therapeutics, 1995-04, Vol.9 (2), p.145
issn 0269-2813
language eng
recordid cdi_pubmed_primary_7605854
source MEDLINE; Access via Wiley Online Library
subjects 2-Pyridinylmethylsulfinylbenzimidazoles
Adult
Aged
Double-Blind Method
Esophagitis, Peptic - drug therapy
Follow-Up Studies
H(+)-K(+)-Exchanging ATPase - pharmacology
Headache - chemically induced
Humans
Lansoprazole
Male
Middle Aged
Omeprazole - adverse effects
Omeprazole - analogs & derivatives
Omeprazole - therapeutic use
Proton Pump Inhibitors
Ranitidine - adverse effects
Ranitidine - therapeutic use
Treatment Outcome
title Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T04%3A06%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lansoprazole%20versus%20ranitidine%20for%20the%20treatment%20of%20reflux%20oesophagitis.%20UK%20Lansoprazole%20Clinical%20Research%20Group&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Bardhan,%20K%20D&rft.date=1995-04&rft.volume=9&rft.issue=2&rft.spage=145&rft.pages=145-&rft.issn=0269-2813&rft_id=info:doi/&rft_dat=%3Cpubmed%3E7605854%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/7605854&rfr_iscdi=true